Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon Gas (NBTX-001) for Symptoms in Parkinson's Disease
NCT04097080Phase 1Unknown
- Sponsor
- Nobilis Therapeutics
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xenon in Parkinson's disease (PD) (2 arms), sponsored by Nobilis Therapeutics. Primary endpoint: Unified Parkinson Disease Rating Scale at Week 24. Status: unknown.
02
Drugs
xenon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04097080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097080.